Gadodiamide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461600

CAS#: 131410-48-5

Description: Gadodiamide is a gadolinium-based MRI contrast agent, used in MR imaging procedures to assist in the visualization of blood vessels.


Price and Availability

Size
Price

500mg
USD 520
Size
Price

Size
Price

Gadodiamide, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 461600
Name: Gadodiamide
CAS#: 131410-48-5
Chemical Formula: C16H29GdN5O8
Exact Mass: 577.1257
Molecular Weight: 576.68
Elemental Analysis: C, 33.32; H, 5.07; Gd, 27.27; N, 12.14; O, 22.19


Synonym: Gadodiamide; DV 7572; DV-7572; DV7572; Omniscan; S 041; S-041; S041;

IUPAC/Chemical Name: A name could not be generated for this structure.

InChi Key: NFPWGFSRWDHFFT-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H29N5O8.Gd/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);

SMILES Code: CNC1=O[Gd+3]234567N(CCN4(CC([O-]6)=O)CC(NC)=O5)(CC([O-]7)=O)CCN2(CC([O-]3)=O)C1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


References

1: Mustafi D, Gleber SC, Ward J, Dougherty U, Zamora M, Markiewicz E, Binder DC, Antic T, Vogt S, Karczmar GS, Oto A. IV Administered Gadodiamide Enters the Lumen of the Prostatic Glands: X-Ray Fluorescence Microscopy Examination of a Mouse Model. AJR Am J Roentgenol. 2015 Sep;205(3):W313-9. doi: 10.2214/AJR.14.14055. PubMed PMID: 26295667; PubMed Central PMCID: PMC4597775.

2: Ramalho J, Semelka RC, AlObaidy M, Ramalho M, Nunes RH, Castillo M. Signal intensity change on unenhanced T1-weighted images in dentate nucleus following gadobenate dimeglumine in patients with and without previous multiple administrations of gadodiamide. Eur Radiol. 2016 Nov;26(11):4080-4088. Epub 2016 Feb 24. PubMed PMID: 26911888.

3: Higuera-Calleja J, Góngora-Rivera F, Soto-Hernández JL, Del-Brutto OH, Moreno-Andrade T, Gutiérrez-Alvarado R, Rodríguez-Carbajal J. Intrathecal gadodiamide for identifying subarachnoid and ventricular neurocysticercosis. Trop Med Int Health. 2015 Jul;20(7):930-3. doi: 10.1111/tmi.12495. Epub 2015 Mar 17. PubMed PMID: 25726723.

4: Quattrocchi CC, Mallio CA, Errante Y, Cirimele V, Carideo L, Ax A, Zobel BB. Gadodiamide and Dentate Nucleus T1 Hyperintensity in Patients With Meningioma Evaluated by Multiple Follow-Up Contrast-Enhanced Magnetic Resonance Examinations With No Systemic Interval Therapy. Invest Radiol. 2015 Jul;50(7):470-2. doi: 10.1097/RLI.0000000000000154. PubMed PMID: 25756685.

5: Nonoyama H, Tanigawa T, Shibata R, Tanaka H, Katahira N, Horibe Y, Takemura K, Murotani K, Ozeki N, Ueda H. Investigation of the ototoxicity of gadoteridol (ProHance) and gadodiamide (Omniscan) in mice. Acta Otolaryngol. 2016 Nov;136(11):1091-1096. Epub 2016 Jun 17. PubMed PMID: 27315460.

6: Homayoon B, Diwakar H, Strovski E, Bakshi D, Harris AC, Thoeni RF, Chang SD. Half-dose gadobenate dimeglumine versus standard-dose gadodiamide in dynamic magnetic resonance imaging of non-cirrhotic livers: a retrospective intra-individual crossover comparison. Abdom Imaging. 2014 Oct;39(5):955-62. doi: 10.1007/s00261-014-0123-z. PubMed PMID: 24676875.

7: Errante Y, Cirimele V, Mallio CA, Di Lazzaro V, Zobel BB, Quattrocchi CC. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol. 2014 Oct;49(10):685-90. doi: 10.1097/RLI.0000000000000072. PubMed PMID: 24872007.

8: Ozawa Y, Hayashi S, Hamasaki Y, Hatamochi A. Effects of Gadodiamide on cell proliferation and collagen production in cultured human dermal fibroblasts. Arch Dermatol Res. 2016 Dec;308(10):695-701. Epub 2016 Sep 28. PubMed PMID: 27683230.

9: Ramalho J, Ramalho M, AlObaidy M, Nunes RH, Castillo M, Semelka RC. T1 Signal-Intensity Increase in the Dentate Nucleus after Multiple Exposures to Gadodiamide: Intraindividual Comparison between 2 Commonly Used Sequences. AJNR Am J Neuroradiol. 2016 Aug;37(8):1427-31. doi: 10.3174/ajnr.A4757. Epub 2016 Mar 31. PubMed PMID: 27032972.

10: Chien CC, Sheu MJ, Chu CC, Sun YM, Kan WC, Wang HY, Hwang JC, Wang JJ. Prophylactic 0.9% saline hydration inhibited high-dose gadodiamide-induced nephropathy in rats. Hum Exp Toxicol. 2012 Nov;31(11):1170-8. doi: 10.1177/0960327112450897. Epub 2012 Jun 26. PubMed PMID: 22736251.

11: Bruce R, Wentland AL, Haemel AK, Garrett RW, Sadowski DR, Djamali A, Sadowski EA. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. Invest Radiol. 2016 Nov;51(11):701-705. PubMed PMID: 26885631.

12: Fretellier N, Idée J, Bruneval P, Guerret S, Daubiné F, Jestin G, Factor C, Poveda N, Dencausse A, Massicot F, Laprévote O, Mandet C, Bouzian N, Port M, Corot C. Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Br J Pharmacol. 2012 Feb;165(4b):1151-62. doi: 10.1111/j.1476-5381.2011.01585.x. PubMed PMID: 21740412; PubMed Central PMCID: PMC3346252.

13: Naganawa S, Kawai H, Taoka T, Suzuki K, Iwano S, Satake H, Sone M, Ikeda M. Cochlear Lymph Fluid Signal Increase in Patients with Otosclerosis after Intravenous Administration of Gadodiamide. Magn Reson Med Sci. 2016 Jul 11;15(3):308-15. doi: 10.2463/mrms.mp.2015-0121. Epub 2016 Feb 3. PubMed PMID: 26841857; PubMed Central PMCID: PMC5608127.

14: Naganawa S, Yamazaki M, Kawai H, Bokura K, Sone M, Nakashima T. Three-dimensional visualization of endolymphatic hydrops after intravenous administration of single-dose gadodiamide. Magn Reson Med Sci. 2013;12(2):147-51. Epub 2013 May 10. PubMed PMID: 23666157.

15: Naganawa S, Yamazaki M, Kawai H, Bokura K, Sone M, Nakashima T. Visualization of endolymphatic hydrops in Ménière's disease after intravenous administration of single-dose gadodiamide at 1.5T. Magn Reson Med Sci. 2013;12(2):137-9. Epub 2013 May 10. PubMed PMID: 23666156.

16: Naganawa S, Yamazaki M, Kawai H, Bokura K, Sone M, Nakashima T. Imaging of Ménière's disease after intravenous administration of single-dose gadodiamide: utility of multiplication of MR cisternography and HYDROPS image. Magn Reson Med Sci. 2013 Mar 25;12(1):63-8. Epub 2013 Mar 11. PubMed PMID: 23474961.

17: Ray DE, Holton JL, Nolan CC, Cavanagh JB, Harpur ES. Neurotoxic potential of gadodiamide after injection into the lateral cerebral ventricle of rats. AJNR Am J Neuroradiol. 1998 Sep;19(8):1455-62. PubMed PMID: 9763378.

18: Saitoh T, Hayasaka K, Tanaka Y, Kuno T, Nagura Y. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med. 2006 Jul;24(6):445-51. PubMed PMID: 16958426.

19: Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol. 1993 Mar;28 Suppl 1:S28-43. Review. PubMed PMID: 8486501.

20: Prince MR, Erel HE, Lent RW, Blumenfeld J, Kent KC, Bush HL, Wang Y. Gadodiamide administration causes spurious hypocalcemia. Radiology. 2003 Jun;227(3):639-46. PubMed PMID: 12773671.